Investor Presentation H1 2023

26 Investor presentation First six months of 2023 Sales growth of 30%, driven by the GLP-1 portfolio for diabetes and obesity treatment Novo NordiskⓇ Novo Nordisk reported quarterly sales DKK billion 60 by therapy Reported sales CAGR1: 10.2% 50 50 Reported sales for the first six months of 2023 Rare Other Rare endocrine rare blood disorders disease disorders Reported sales and growth breakdown for the first six months of 2023 Therapy Sales (mDKK) Growth Share of growth Injectable GLP-12 46,392 44% 56% RybelsusⓇ 8,344 98% 17% 40 40 -5.5%¹ 1% 5% 2% Total GLP-1 54,736 50% 73% Total insulin³ 24,697 -7% -8% Obesity Other Diabetes care4 -4.5%¹ 1,396 -19% -2% care 17% 30 Total Diabetes care 80,829 24% 63% 20 20 1.6%1 12.1 %1 Obesity care5 18,148 157% 44% Diabetes and Obesity care 98,977 37% 107% Rare blood disorders 5,885 -1% 0% 75% 10 Rare endocrine disorders? 2,030 -46% -7% Diabetes care 0 Other Rare disease Rare disease 775 -11% 0% 8,690 -18% -7% Q2 Other rare disease 2013 Rare endocrine disorders Q2 2023 Total 107,667 30% 100% Rare blood disorders Diabetes and Obesity care Sales of DKK 107.7 billion (+29%) 1 CAGR for 10-year period; 2 Comprises Victoza®, Ozempic®; 3 Comprises Tresiba®, XultophyⓇ and Levemir®, RyzodegⓇ and NovoMix®,FiaspⓇ and Novo RapidⓇ: 4 Primarily NovonormⓇ, needles and Gluca Gen® HypoKitⓇ; 5 Comprises SaxendaⓇ and Wegovy®: 6 Comprises NovoSeven®, Novo Eight®, NovoThirteenⓇ Refixia®, and Esperoct®; 7 Comprises NorditropinⓇand Macrilen TM; 8 Primarily VagifemⓇ and ActivelleⓇ Note: Sales numbers are reported in Danish kroner; Growth is at constant exchange rate, except for total sales growth of 29%; Refixia® and NovoThirteenⓇ are launched as RebinynⓇ and TRETTENⓇ, respectively, in North America.

View entire presentation